Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8 + T-cell density and activity, and enlarges draining lymph nodes

Journal of Immunotherapy

Volumn 33, Issue 3, 2010, Pages 236-249

  Søndergaard, Henrik ^a   Galsgaard, Elisabeth D ^a   Bartholomaeussen, Monica ^a   Straten, Per Thor ^b   Ødum, Niels ^c   Skak, Kresten ^a  

^a NOVO NORDISK A S   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; Draining lymph nodes; Interleukin 21; Intratumoral; Melanoma; Renal cell carcinoma; T cells; Tumor infiltrating lymphocytes

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 21; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL COUNT; CELL DENSITY; CELL INFILTRATION; CONTROLLED STUDY; DEGRANULATION; DRUG EFFICACY; FEMALE; KIDNEY CARCINOMA; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; GRANZYMES; IMMUNITY; INJECTIONS, INTRALESIONAL; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; INTERLEUKINS; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; LYMPH NODES; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954913436     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181c0c1cb     Document Type: Article

References (56)

1. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.
2. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
3. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654-2666.
4. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-2593.
5. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-3494.
6. Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67:354-361.
7. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538-18543.
8. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007;104:3967-3972.
9. Schumacher K, Haensch W, Roefzaad C, et al. Prognostic significance of activated CD8 (+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001;61:3932-3936.
10. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-213.
11. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
12. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131-145. (Pubitemid 44401498)
13. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57-63.
14. Bryant VL, Ma CS, Avery DT, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol. 2007;179:8180-8190.
15. Wei L, Laurence A, Elias KM, et al. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem. 2007;282:34605-34610.
16. Wurster AL, Rodgers VL, Satoskar AR, et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gammaproducing Th1 cells. J Exp Med. 2002;196:969-977.
17. Chtanova T, Tangye SG, Newton R, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol. 2004;173:68-78.
18. Coquet JM, Kyparissoudis K, Pellicci DG, et al. IL-21 Is Produced by NKT Cells and Modulates NKT Cell Activation and Cytokine Production. J Immunol. 2007;178:2827-2834.
19. Harada M, Magara-koyanagi K, Watarai H, et al. IL-21-induced Bepsilon cell apoptosis mediated by natural killer T cells suppresses IgE responses. J Exp Med. 2006;203:2929-2937.
20. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 2008;26:57-79.
21. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol. 2005;5:688-698.
22. Davis ID, Brady B, Kefford RF, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 2009;15:2123-2129.
23. Davis ID, Skrumsager BK, Cebon J, et al. An open-label, twoarm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res. 2007;13:3630-3636.
24. Frederiksen KS, Lundsgaard D, Freeman JA, et al. IL. ILLncer Immunol Immunother. 2008;57:1439-1449.
25. Sondergaard H, Frederiksen KS, Thygesen P, et al. Interleukin 21 therapy increases the density of tumor infiltrating CD8 (+) T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother. 2007;56:1417-1428.
26. Den OW, Jacobs JJ, Battermann JJ, et al. Local therapy of cancer with free IL-2. Cancer Immunol Immunother. 2008;57:931-950.
27. Skak K, Kragh M, Hausman D, et al. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov. 2008;7:231-240.
28. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer. 2003;89:1620-1626.
29. Scheffer SR, Nave H, Korangy F, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer. 2003;103:205-211.
30. Krup OC, Kroll I, Bose G, et al. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. J Immunother. 1999;22:525-538.
31. Overwijk WW. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol. 2005;17:187-194.
32. Kasaian MT, Whitters MJ, Carter LL, et al. IL. ILLmunity. 2002;16:559-569.
33. Zeng R, Spolski R, Finkelstein SE, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med. 2005;201:139-148.
34. Liu S, Lizee G, Lou Y, et al. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol. 2007;19:1213-1221.
35. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005;175:2261-2269.
36. Ostiguy V, Allard EL, Marquis M, et al. IL-21 promotes T lymphocyte survival by activating the phosphatidylinositol-3 kinase signaling cascade. J Leukoc Biol. 2007;82:645-656.
37. Moroz A, Eppolito C, Li Q, et al. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol. 2004;173:900-909.
38. Li Y, Yee C. IL. ILLood. 2008;111:229-235.
39. Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003;9:1377-1382.
40. Di Carlo E, Comes A, Orengo AM, et al. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol. 2004;172:1540-1547.
41. Furukawa J, Hara I, Nagai H, et al. Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J Urol. 2006;176:1198-1203.
42. Caruso R, Fina D, Peluso I, et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gaastroenterology. 2007;132:166-175.
43. Wuest TY, Willette-Brown J, Durum SK, et al. The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells. J Leukoc Biol. 2008;84:973-980.
44. Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol. 2007;178:732-739.
45. Kim-Schulze S, Kim HS, Fan Q, et al. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther. 2008;17:380-388.
46. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448:480-483.
47. Ma HL, Whitters MJ, Konz RF, et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFNgamma. J Immunol. 2003;171:608-615.
48. Ugai S, Shimozato O, Kawamura K, et al. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther. 2003;10:187-192. (Pubitemid 36348679)
49. Ugai S, Shimozato O, Yu L, et al. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and-independent antitumor effects. Cancer Gene Ther. 2003;10:771-778.
50. Gagnon J, Ramanathan S, Leblanc C, et al. IL-6, in synergy with IL-7 or IL-15, stimulates TCR-independent proliferation and functional differentiation of CD8+ T lymphocytes. J Immunol. 2008;180:7958-7968.
51. Hinrichs CS, Spolski R, Paulos CM, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 2008;111:5326-5333.
52. Ferrari-Lacraz S, Chicheportiche R, Schneiter G, et al. IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytes. Int Immunol. 2008;20:1009-1018.
53. Jin H, Carrio R, Yu A, et al. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol. 2004;173:657-665.
54. Iuchi T, Teitz-Tennenbaum S, Huang J, et al. Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses. Cancer Res. 2008;68:4431-4441.
55. Nakano H, Kishida T, Asada H, et al. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J Gene Med. 2006;8:90-99.
56. Daga A, Orengo AM, Gangemi RM, et al. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer. 2007;121:1756-1763.